Tag Archives: Glioblastoma Multiforme

May, 2017

8 May
Regeneron and Inovio Enter Agreement for Glioblastoma Combination Therapy

TARRYTOWN, N.Y. and PLYMOUTH MEETING, Pa., May 8, 2017 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced a clinical study agreement for a Phase 1b/2a immuno-oncology trial. The study will be conducted by Inovio in patients with newly-diagnosed glioblastoma multiforme (GBM) and will …
Share

7 February
GW Pharma’s Cannabis-Derived Drug Shows Promise in Brain Cancer Study

London, UK, 7 Feb 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced positive top-line results from an exploratory Phase 2 placebo-controlled clinical study of a proprietary combination …
Share

31 October
Roche Licenses its PI3K Pathway Brain Cancer Drug to Novogen

SYDNEY, Oct. 30, 2016 /PRNewswire/ — Australian oncology-focused biotechnology company, Novogen Ltd (ASX: NRT; NASDAQ: NVGN) today announced that it has entered into a worldwide licensing agreement with Genentech, a member of the Roche Group, to develop and commercialize GDC-0084, a small molecule inhibitor of the phosphoinositide-3-kinase (PI3K) pathway. The …
Share

27 July
NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed GBM

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the National Comprehensive Cancer Network (NCCN) has recommended Optune as a standard treatment option for newly diagnosed glioblastoma (GBM) in its Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers. NCCN panel members designated Optune together with temozolomide …
Share

7 March
Celldex Discontinues its Late-Stage Brain Cancer Vaccine Study

HAMPTON, N.J., March 07, 2016 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the independent Data Safety and Monitoring Board (DSMB) has determined, based on a preplanned interim analysis, that continuation of the Phase 3 ACT IV study of RINTEGA® (rindopepimut) in patients with newly diagnosed EGFRvIII-positive glioblastoma …
Share